logo
Almost 2.5m people in England likely to have ADHD, data shows

Almost 2.5m people in England likely to have ADHD, data shows

It is the first time an estimate has been made publicly available of how common the condition may be among the population.
ADHD is a neuro-developmental disorder and people with the condition may have trouble concentrating or sitting still.
(PA Graphics)
Other symptoms include being easily distracted, forgetfulness, finding it hard to follow instructions or organise time, and making impulsive decisions.
According to NHS England, a total of 2,498,000 people may have ADHD, including those without a diagnosis.
Of this number, an estimated 741,000 are children and young people aged five to 24.
The figures were developed using estimates from the National Institute for Health and Care Excellence (Nice), which suggests that around 3-4% of adults and 5% of children and young people have ADHD.
While ADHD is not usually diagnosed in children under five – as some traits can be part of typical development – prevalence in youngsters aged four and under have been calculated to give an insight into how many may go on to be diagnosed in the future.
(PA Graphics)
Some 147,000 under-fives are likely to have ADHD, according to the NHS estimates.
The figures also suggest that more than half a million people (549,000) in England were waiting for an ADHD assessment at the end of March 2025.
This is up from 416,000 a year earlier at the end of March 2024.
Of the 549,000 likely to be waiting for ADHD assessment in March this year, some 304,000 had been waiting at least a year while 144,000 had been waiting at least two years.
More than two-thirds (382,000) were aged between five and 24.
Louise Ansari, chief executive at Healthwatch England, said the figures are 'a first step in understanding the scale of demand for ADHD care'.
'Our new research highlights that many people with ADHD may simply be going without support,' she added.
'Long waits for assessments are one of the reasons people who show ADHD traits don't seek help, while those waiting for an assessment struggle to navigate the long waits.
'While we welcome today's publication, however, there is a way to go to ensure data is comprehensive and robust.
'A move to official waiting list data in the longer term would give a clearer picture of waiting times, including who is experiencing the longest waits and why.'
Estimates of how many adults in England are likely to be waiting for ADHD assessments is available dating back to 2019.
They show the the number of people aged 25 and over who were waiting at the end of March was 165,000, more than 10 times the pre-pandemic figure of 16,000 at the end of December 2019.
Comparable data for children and young adults is available only for the most recent 12 months and shows the number rose from an estimated 285,000 at the end of March 2024 to 384,000 at the end of March this year.
Pippa Sargent, chief executive of The Brain Charity, said: 'It's a hugely positive step that more people are coming forward for ADHD assessments. This shows increasing awareness, self-advocacy and a shift in how society understands neurodiversity.
'It is important to remember that, despite its challenges, the condition brings with it many strengths that should be celebrated.
'But with up to 549,000 people now waiting, the scale of unmet need is alarming. Without urgent investment in diagnostic services and ongoing support, too many are being left to struggle alone.'
An NHS spokesperson said: 'Patients are waiting too long for an ADHD assessment and diagnosis and that's why the NHS launched an independent taskforce to investigate the challenges facing services and help them manage the rising numbers of referrals, with support from across society.
'The ADHD taskforce will assess these important new figures and the best available evidence to inform its recommendations, bringing together those with lived experience and experts across a range of sectors to help find long-term solutions for patients.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS ‘passports' will see new innovations rolled out to cut red tape
NHS ‘passports' will see new innovations rolled out to cut red tape

Telegraph

timean hour ago

  • Telegraph

NHS ‘passports' will see new innovations rolled out to cut red tape

Mr Streeting said it would mean an end to the 'postcode lottery for life-saving products', while 'companies will be able to get their technology used across the NHS more easily'. An example of such innovations include special wound dressings, rapid flu testing and artificial intelligence appointment booking platforms. New wound dressings are reducing infections by 38 per cent at Barking, Havering ∧ Redbridge University Hospitals and could be adopted across the country, the Department of Health said. Rapid flu testing at University Hospitals Dorset has cut the time patients spend in hospital alongside antibiotic use. Roll out of technology Dr Benyamin Deldar, a clinical entrepreneur fellow at NHS England and the co-founder of Deep Medical, which runs an AI booking system already used by some NHS hospitals, told The Telegraph it would save up to 'six months of red tape'. The AI system predicts no-shows based on a range of factors and maximises doctors time by reducing the chance of a missed appointment, cutting them by up to 30 per cent. 'Deploying in each new trust can take up to nine months because the same Information Governance checks are repeated; an 'innovator passport' would cut between three to six months of red tape, letting patients benefit far sooner,' said Dr Deldar. The passport will be introduced over the next two years and will mean technology that has been robustly assessed by one NHS organisation can easily be rolled out to others. The Department of Health said this would remove 'needless bureaucracy' and create a 'dynamic best buyer's guide', while also helping boost economic growth. MedTech Compass aims to make these innovations, and the evidence underpinning them, clearer to buyers within the NHS. 'Positive step' Dr Vin Diwakar, the clinical transformation director at NHS England, said: 'We're seeing the impact improvements to technology are having on our everyday lives on everything from smartwatches to fitness trackers – and we want to make sure NHS patients can benefit from the latest medical technology and innovations as well. 'The new innovator passports will speed up the rollout of new health technology in the NHS which has been proven to be effective, so that patients can benefit from new treatments much sooner.' Matthew Taylor, chief executive of the NHS Confederation, which represents health organisations, said it was a 'positive step towards reducing duplication, making innovation more agile and accessible, and streamlining how technology is rolled out across the health service'. 'But it will be vital to ensure that important compliance processes are also kept in place to safeguard clinical and patient safety, data protection and strict Medtech regulation,' he added.

Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast cancer patients ‘denied life-extending drugs because of unfair system'

Rhyl Journal

time5 hours ago

  • Rhyl Journal

Breast cancer patients ‘denied life-extending drugs because of unfair system'

Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'

Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast cancer patients ‘denied life-extending drugs because of unfair system'

North Wales Chronicle

time5 hours ago

  • North Wales Chronicle

Breast cancer patients ‘denied life-extending drugs because of unfair system'

Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store